SWK Holdings Corporation Acquires Enteris BioPharma

SWK Holdings Corporation acquires 100% of Enteris’ equityEnteris to operate as an independent, wholly-owned subsidiary of SWK, targeting opportunities to develop and advance orally delivered peptide and small molecule therapeuticsNatural extension of SWK’s life...

SWK Holdings Corporation Announces Share Repurchase Program

Dallas, TX, December 6, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, today announced that its Board of Directors has authorized the Company to repurchase up to an aggregate of $3,500,000 of the Company’s Common Stock from time to time until May 31, 2019 through a “10b5-1 trading plan” in compliance with Rule 10b-18 under the Securities Exchange Act of 1934.